-
Improving innovation capabilities has become a general trend in the industry, and pharmaceutical
Time of Update: 2023-02-03
In the future, pharmaceutical equipment companies will continue to increase investment in research and development (Image source: Pharmaceutical Network) It is reported that in China, the head pharmaceutical machine companies represented by Chutian Technology and Dongfulong have been continuously increasing investment in research and development, constantly enriching product categories, optimizing product structure, actively deploying new tracks such as biopharmaceuticals and vaccines, and continuously meeting the downstream localization replacement needs while promoting the high-quality development of the industry.
-
AI pharmaceutical research and development is hot, and transaction cooperation has gradually become an industry trend
Time of Update: 2023-01-06
On October 11, Illumina announced a strategic research collaboration with AstraZeneca to accelerate drug target discovery by combining the strengths of both companies in artificial intelligence (AI)-based genome interpretation and genomic analysis technologies, as well as industry expertise.
-
AI pharmaceutical research and development is hot, and transaction cooperation has gradually become an industry trend
Time of Update: 2023-01-06
On October 11, Illumina announced a strategic research collaboration with AstraZeneca to accelerate drug target discovery by combining the strengths of both companies in artificial intelligence (AI)-based genome interpretation and genomic analysis technologies, as well as industry expertise.
-
Under the trend of innovation, the upstream and downstream of the pharmaceutical industry chain are increasing investment in research and development
Time of Update: 2022-11-04
com) Pharmaceutical companies are investing in R&D increasing Taking Warner Pharma as an example, on October 31, Warner Pharma disclosed its third quarter report for 2022.
com) Pharmaceutical companies are investing in R&D increasing Taking Warner Pharma as an example, on October 31, Warner Pharma disclosed its third quarter report for 2022.
-
Shanghai Pharmaceutical strengthens innovation and research and development to promote the high-quality development of the biomedical industry
Time of Update: 2022-09-30
Recently, when Shanghai Pharmaceutical was surveyed by investors, it said that the company's clinical applications have been accepted and entered the clinical research stage of the new drug pipeline
-
The overall R&D expense rate of the pharmaceutical industry continues to rise, and these high-input
Time of Update: 2022-09-30
In the first half of this year, the total R&D investment of Healthy Yuan was 805 million yuan, an increase of 15.
In the first half of this year, the total R&D investment of Healthy Yuan was 805 million yuan, an increase of 15.
-
Competing for the fourth revolutionary wave in the pharmaceutical industry: antibody drug research and development opens the "Neptune Plan"
Time of Update: 2022-09-21
As mentioned above, in the field of tumor treatment alone, dual antibodies have completely exploded, and the research and development of antibody drugs with more targets such as three antibodies and four antibodies is also in full swing.
-
The pharmaceutical industry has set off a wave of AI research and development, and it will also have great prospects in the pharmaceutical field
Time of Update: 2022-08-15
[Pharmaceutical Network Market Analysis] With the help of AI pharmaceuticals, it can improve the speed of new drug research and development and reduce costs, and help pharmaceutical companies to spee
-
The prosperity of the innovative drug industry is gradually heating up, and pharmaceutical
Time of Update: 2022-05-11
R&D investment has continued to increase, and at the same time, a large number of companies have actively introduced clinical-stage products through authorized cooperation, resulting in the continuous emergence of first-in-class and fast-follower drugs in the domestic market .
-
Institutions get together to investigate the pharmaceutical industry, these four pharmaceutical
Time of Update: 2022-04-25
During the research process, Teyi Pharmaceutical revealed that the comprehensive gross profit rate of the company's proprietary Chinese medicines is above 70%, and Zhikebao tablets are the company's core product, and the gross profit rate has been maintained at above 80% .
-
SINBON Pharmaceuticals Receives Research from 10 Institutions: National Chinese Medicine Industry Policy Brings Positive Impact on the Company
Time of Update: 2021-11-13
The main business structure of traditional Chinese medicine has built a "medical service +" platform operation model, realized resource sharing, and highlighted the platform's advantages such as strong anti-risk ability, high management efficiency, and low financing cost .
-
The pharmaceutical industry has set off a financing wave, and pharmaceutical companies will accelerate the research and development of new drugs
Time of Update: 2021-11-12
. It is reported that this round of financing will be used to continue to promote the development of domestic and foreign clinical research trials of multiple drug candidates including AGA111, continue to expand the scale of the preclinical product pipeline, and further improve the creation of a management team with international experience and vision , To accelerate the industrialization of innovative drugs in the treatment of severe bone, joint and muscle diseases .
-
the research and development expense investment of the pharmaceutical company
Time of Update: 2021-09-11
In addition, in recent years, Zhongsheng Pharmaceutical’s R&D investment has continued to increase, and 50% of the projects entering the clinical stage are independent research and development products .
-
CDE: The research and development standards of new anti-tumor drugs need to be improved in the pharmaceutical industry led by CXO.
Time of Update: 2021-08-11
In the long run, it will help encourage "true innovation" with clinical value, reduce homogenized competition, and guide domestic new drug development to participate in global market competition at a higher level .
-
The transformation of the pharmaceutical industry accelerates the multi-point flowering of innovative drug research and development
Time of Update: 2021-02-27
The first impression investors gave investors of the 2009 listing was that the business was sound, and that there had not been a year of declining performance in the nine years since the listing. In 2
